Ionis Pharmaceuticals (IONS) Operating Income (2009 - 2026)

Ionis Pharmaceuticals' Operating Income history runs 18 years deep, the most recent figure standing at -$117.4 million for Q1 2026.

• On a quarterly basis, Operating Income rose 20.04% year-over-year to -$117.4 million in Q1 2026; TTM through Mar 2026 was -$352.2 million, a 25.44% increase from a year earlier, with the FY2025 full-year figure at -$381.7 million, up 19.66% from the prior year.
• Operating Income grew to -$117.4 million in Q1 2026 per IONS's latest filing, from -$214.5 million in the prior quarter.
• Across five years, Operating Income topped out at $139.8 million in Q2 2025 and bottomed at -$214.5 million in Q4 2025.
• The 5-year median for Operating Income is -$114.1 million (2023), against an average of -$102.2 million.
• Across the five-year window, Operating Income plunged 1710.21% in 2024 and surged 311.55% in 2025, its largest moves.
• Year by year, Operating Income stood at -$208.0 million in 2022, then jumped by 97.06% to -$6.1 million in 2023, then plunged by 1710.21% to -$110.8 million in 2024, then plunged by 93.52% to -$214.5 million in 2025, then surged by 45.25% to -$117.4 million in 2026.
• Per Business Quant, the three latest IONS Operating Income figures stand at -$117.4 million (Q1 2026), -$214.5 million (Q4 2025), and -$160.2 million (Q3 2025).